Coultreon Biopharma

Private

Belgian immunology biotech (formerly Onco3R Therapeutics) developing COL-5671, an oral SIK3 inhibitor targeting psoriasis and ulcerative colitis. The aim is biologic-class efficacy delivered as a once-daily pill, with the lead asset transferred from Galapagos in 2025.

Founders Andrew Phillips

CEO Andrew Phillips

Company

Founded

2025

Headquarters

Leuven, Belgium

Financials

Total Funding

$148M

Sectors

Healthtech Biotech

coultreon.com

Funding History

2 rounds

Series A Apr 28, 2026

$125M

Sofinnova Investments (Lead) Forbion Novo Holdings Galapagos NV Regeneron Ventures Balyasny Asset Management Luma Group Samsara BioCapital Longwood Fund Finchley Healthcare Ventures

Convertible Note Apr 15, 2025

$23M

Galapagos NV (Lead)

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.